ALPMY News and Press, Astellas Pharma Inc. ADR From 11/29/23

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy PR Newswire Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant redu...

2023-11-19 21:37:59 ET Summary Soros Fund Management's 13F portfolio value increased by 10% to $7.05B, with 209 positions. Top three individual stocks held were Horizon Therapeutics, Activision Blizzard, and Alphabet. New stakes included Activision Blizzard, Abcam plc, Novo No...

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting PR Newswire XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive...

University of Tsukuba and Astellas Confirm a Strategic Partnership PR Newswire - Accelerating the development of the life science ecosystem centered on Tsukuba - - Promoting innovative drug discovery research using AI and digital technologies and creating new drug ...

Astellas to Acquire Propella Therapeutics PR Newswire - Acquire PRL-02, prostate cancer treatment program being developed by Propella Therapeutics - TOKYO and PITTSBORO, N.C. , Nov. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, Pr...

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology PR Newswire Preliminary data analysis on ventilator dependence and motor improvement are reported alongside overall safety findings TOKYO , Nov. 15, 20...

2023-11-07 19:06:24 ET Summary A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical conference. EPI-7386 is being advanced as a monot...

2023-11-05 12:17:29 ET Summary The UST yield curve has steepened and this could provide an opportunity to buy US banking stocks on weakness in a no-recession scenario. Japan and Eurozone exporters can benefit from a global downturn due to easier central bank policies depreciating ...

IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years PR Newswire Phase 3 results presented at the AAO Annual Meeting demonstrated the IZERVAY treatment effect more than doubled over...

FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...